New therapies requiring ultra large scale monoclonal Ab production in microalgae

点击翻译按钮获取中文摘要

Monoclonal antibodies target pathogens and molecules with exquisite specificity, and are essential for therapeutics and diagnostics. They are currently made using high-tech/limited-capacity mammalian cell cultures which limit them to low-dose applications. We aim to enable new, high-dose antibody therapies (e.g. antiviral treatments, passive immunisation) via rapid, low-cost, dramatically larger-scale production of valuable medicinal antibodies in a photosynthetic-driven, green algae system.